93643-24-4

Basic information

• Product Name: (S)-1,4-DIAZABICYCLO[4.3.0]NONANE
• Synonyms: (S)-Octahydro-pyrrolo[1,2-a]pyrazine;(6S)-1,4-Diazabicyclo[4.3.0]nonane;(S)-1,4-Diazabicyclo[4.3.0]nonane, 98+%;Pyrrolo[1,2-a]pyrazine, octahydro-, (8aS)-;(8aS)-octahydropyrrolo[1,2-a]piperazine;(8AS)-OCTAHYDROPYRROLO[1,2-A]PYRAZINE;(S)-1,4-DIAZABICYCLO[4.3.0]NONANE;Pyrrolo[1,2-a]pyrazine, octahydro-, (8aS)- (9CI)
• CAS NO: 93643-24-4
• Molecular Formula: C₇H₁₄N₂
• Molecular Weight: 126.2
• Product Categories: PIPERAZINE
• Mol File: 93643-24-4.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 199.639ºC at 760 mmHg
• Flash Point: 88.833ºC
• Appearance: /
• Density: 1.036g/cm3
• Vapor Pressure: 0.338mmHg at 25°C
• Refractive Index: 1.534
• Storage Temp.: 2-8°C(protect from light)
• PKA: 9.98±0.20(Predicted)
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: (S)-1,4-DIAZABICYCLO[4.3.0]NONANE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1,4-DIAZABICYCLO[4.3.0]NONANE(93643-24-4)
• EPA Substance Registry System: (S)-1,4-DIAZABICYCLO[4.3.0]NONANE(93643-24-4)

Safety Data

• Hazard Codes: Xi
• RIDADR: UN3267
• HazardClass: 8
• Hazardous Substances Data: 93643-24-4(Hazardous Substances Data)

Usage

Uses

(S)-1,4-Diazabicyclo[4.3.0]nonane is used as stationary phases for the separation of enantiomeric mixtures of products. It is also used as catalysts for the enantioselective synthesis of various organic compounds and drugs.

InChI:InChI=1/C7H14N2/c1-2-7-6-8-3-5-9(7)4-1/h7-8H,1-6H2/t7-/m0/s1

Upstream product

• 57294-31-2 tert-butyl (S)-2-((2-ethoxy-2-oxoethyl)carbamoyl)pyrrolidine-1-carboxylate 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 38074-72-5 (S)-1-(2-chloroacetyl)pyrrolidine-2-carboxylic acid methyl ester 
• 862671-86-1 benzyl (S)-hexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate 
• 5817-26-5 ethyl (2S)-pyrrolidine-2-carboxylate 
• 147-85-3 L-proline 
• 96163-74-5 N-chloroacetyl-L-proline ethyl ester 
• 634922-10-4 [(pyrrolidine-2-carbonyl)-amino]acetic acid methyl ester trifluoroacetate 
• 15761-39-4 N-Boc-L-proline 
• 3705-27-9 (S)-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione 
• 96145-91-4 L-5-Oxo-1,4-diazabicyclo<4.3.0>nonane 

Downstream Products

• 102535-38-6 3-((S)-Hexahydro-pyrrolo[1,2-a]pyrazine-2-carbonyl)-4-methoxy-benzenesulfonamide 
• 1245465-53-5 N-[5-[4-{5-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-ylmethyl]-1,3,4-oxadiazol-2-yl}-1-(phenylsulfonyl)-1H-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide 
• 1235560-13-0 (S)-3-(octahydropyrrolo[1,2-a]pyrazine-2-carbonyl)-N-(4-(trifluoromethyl)phenyl)benzenesulfonamide 
• 1235560-16-3 (S)-N-(2,3-difluorophenyl)-3-(octahydropyrrolo[1,2-a]pyrazine-2-carbonyl)benzenesulfonamide 
• 1235560-24-3 (S)-N-(2-fluorophenyl)-3-(octahydropyrrolo[1,2-a]pyrazine-2-carbonyl)benzenesulfonamide 
• 1259917-21-9 (S)-N-cyclohexyl-2-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)acetamide 
• 1338729-53-5 C₃₀H₃₅N₃O₆ 
• 1338708-20-5 C₃₀H₃₃FN₂O₅ 
• 1338706-11-8 (S)-(2-chloro-3,4-bis((4-methoxybenzyl)oxy)phenyl) (hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)methanone 
• 1374675-88-3 (S)-3-((S)-2-Chloro-4-hexahydro-pyrrolo[1,2-a]pyrazin-2-yl-benzenesulfonyl)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1333491-55-6 C₁₈H₂₂N₄O 
• 639069-01-5 C₂₄H₃₃N₃O₂ 
• 1245465-57-9 6-bromo-4-{5-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-ylmethyl]-1,3,4-oxadiazol-2-yl}-1-(phenylsulfonyl)-1H-indazole 
• 1235560-05-0 N-(3-fluorophenyl)-3-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-ylcarbonyl]benzenesulfonamide 

Relevant articles and documents

CERTAIN PROTEIN KINASE INHIBITORS

Provided are certain CDK4/6 inhibitors, pharmaceutical compositions thereof, and methods of use therefor.

Design, synthesis, and structure-activity relationship study of bicyclic piperazine analogs of indole-3-carboxamides as novel cannabinoid CB1 receptor agonists

Bicyclic piperazine derivatives were synthesized as conformationally constrained analogs of N-alkyl piperazines and were found to be potent CB1 receptor agonists. The CB1 receptor agonist activity was dependent upon the absolute configuration of the chiral center of the bicyclic ring system. Although the conformational constraint did not protect the compounds from metabolism by N-dealkylation, several bicyclic analogs were found to be more potent than the unconstrained lead compound. Compound 8b demonstrated potent antinociceptive activity in vivo.

BICYCLIC NONANE AND DECANE COMPOUNDS HAVING DOPAMINE RECEPTOR AFFINITY

Described herein are D4 receptor-selective compounds of the general formula: STR1 wherein: A and B are independently selected, substituted or unsubstituted, unsaturated 5-or 6-membered, homo-or heterocyclic rings;X 1 is selected from O, S, SO, SO 2, CH. sub.2, C=O, CH--OH, CH--N(C 1-4 alkyl) 2, C= CHCl, and C=CHCN;X 2---is selected from N= , CH. sub.2--, CH= and C(O)--;n is 1 or 2; R 1 is selected from H and the α-carbon side chain of an amino acid;R 2 and R 3 are selected independently from H, OH,--NH 2,--C(O)NH 2 =O, =S,halo, cyano, C 1-9 alkyl, C 1-9 alkoxy, C 1-4 alkylS--, C 1-4 alkylSO--, C 1-4 alkylSO 2--, phenoxy, benzyloxy and piperonyloxy; andH* is in either the R-or the S-configuration,and acid addition salts, solvates and hydrates thereof.Their use as ligands for dopamine receptor identification and in a drug screening program, and as pharmaceuticals to treat indications in which the D4 receptor is implicated, such as schizophrenia, is also described.